0001140361-17-023349.txt : 20170601 0001140361-17-023349.hdr.sgml : 20170601 20170601173923 ACCESSION NUMBER: 0001140361-17-023349 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170510 FILED AS OF DATE: 20170601 DATE AS OF CHANGE: 20170601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE CENTRAL INDEX KEY: 0000874716 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010393723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 BUSINESS PHONE: 2075560300 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 FORMER COMPANY: FORMER CONFORMED NAME: IDEXX CORP / DE DATE OF NAME CHANGE: 19600201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AYERS JONATHAN W CENTRAL INDEX KEY: 0001184149 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19271 FILM NUMBER: 17885813 MAIL ADDRESS: STREET 1: IDEXX LABORATORIES, INC. STREET 2: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092 4/A 1 doc1.xml FORM 4/A X0306 4/A 2017-05-10 2017-05-11 0 0000874716 IDEXX LABORATORIES INC /DE IDXX 0001184149 AYERS JONATHAN W ONE IDEXX DRIVE WESTBROOK ME 04092 1 1 0 0 Chairman, President & CEO Common Stock 2017-05-10 4 M 0 10000 38.7950 A 1024994 D Common Stock 2017-05-10 4 S 0 10000 162.3092 D 1014994 D Common Stock 2017-05-10 4 M 0 20000 38.7950 A 1034994 D Common Stock 2017-05-10 4 S 0 6200 162.2830 D 1028794 D Common Stock 2017-05-10 4 S 0 10800 163.2760 D 1017994 D Common Stock 98000 I by Ayers Family Trust Non-Qualified Stock Option (right-to-buy) 38.7950 2017-05-10 4 M 0 10000 D 2018-02-13 Common Stock 10000 0 D Non-Qualified Stock Option (right-to-buy) 38.7950 2017-05-10 4 M 0 20000 D 2018-02-13 Common Stock 20000 380000 D Represents the weighted average sales price of the shares sold ranging from a low of $161.55 to a high of $162.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Represents the weighted average sales price of the shares sold ranging from a low of $161.95 to a high of $162.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Represents the weighted average sales price of the shares sold ranging from a low of $163.04 to a high of $163.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Not applicable. Amendment filed due to scrivener's error in the calculation of the number of shares held at the completion of the transactions. /s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers 2017-06-01